Home/Pipeline/XmAb®662

XmAb®662

Infectious Disease

PreclinicalActive

Key Facts

Indication

Infectious Disease

Phase

Preclinical

Status

Active

Company

Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Infectious Disease

Other Infectious Disease Drugs

Drug	Company	Phase	Status
Vaccine Platform	Biolingus	Research	Active
Pipeline Antibiotics	BioQ Pharma	Unknown	Active
Antivirals Platform	Qubit Pharmaceuticals	Discovery	Active
Antibiotic Development Program	AF ChemPharm	Pre-clinical	Active
Prophylactic Vaccine Development	ImmuneSpec	Service	Active
Optimized VHH vs. SARS-CoV-2	Ordaos Bio	Pre-clinical	Active
Undisclosed Vaccine Program(s)	Brazos Biomedical	Pre-clinical	Active
Undisclosed Asset 1	Uvax Bio	Research	Active
Undisclosed Asset 2	Uvax Bio	Research	Active
Undisclosed Asset 3	Uvax Bio	Research	Active
Vaccine Immune Response (SARS-CoV-2)	CellChorus	Preclinical	Active
C1-based Therapeutic Antigen	Dyadic	Phase I	Completed